[The clinical effectiveness of rabeprazole in patients with acid-related gastric and duodenal diseases with various sensitivity of different types of parietal gastric cell receptors].
The authors studied the duration of intragastric acid production at 20 mg of pariet in patients with hypergastric gastritis after determination of the individual type of parietal gastric cell reception. The study included 40 patients (12 women and 28 men aged 33.3 +/- 6.7 years). Predominant activity of H2 receptors was detected in 32 patients, while M-cholinoreceptor activity prevailed in six patients; in two patients receptor type was not defined. Latent period (3.1 +/- 0.5 hours), pH(max) (5.4 +/- 0.7), pH24h (3.5 +/- 0.4), pH(stimulated24h) (3.0 +/- 0.7) did not depend on the predominant sensitivity of either receptor type and was significantly higher in patients taking pariet than in patients receiving standard doses of omeprazole (2.2 +/- 0.5 h, 4.0 +/- 0.3, 2.4 +/- 0.3, and 1.2 +/- 0.3, respectively) or lansoprazole (2.2 +/- 0.6, 4.3 +/- 0.6, 2.6 +/- 0.3, and 1.3 +/- 0.3, respectively). The clinical effectiveness of pariet was evaluated in 20 patients (15 men and 5 women aged 51.6 +/- 5.4) after gastric resection, needing antisecretory therapy. Individual reception type was studied. The effects of pirenzepine and ranitidine (or famotidine) given in standard doses at the beginning of the week were studied in patients with predominant H2-hystaminergic, M-cholinergic, or unclear type. After that all patients received pariet 20 mg a day. None of the patients displayed predominant H2 receptor activity. In 14 patients predominant M-cholinoreceptor activity was noted; in six patients receptor type remained unclear. All the patients were administered ranitidine (or famotidine) during one week with no clinical effect. Six patients with unclear reception type were given gastrozepine for one more week, with no effect either. After the beginning of pariet 20 mg a day complaints disappeared in all patients within one or two days. The conclusion is that pariet in a standard dose possesses higher antisecretory effect vs. other proton pump inhibitors, unlike that of H2 histamine blockers, the latter not depending on the individual type of gastric parietal cell reception.
Serebrova
S Iu
SIu
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005745:Gastric Acidity Determination; D005756:Gastritis / Q000188:drug therapy*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D064747:Lansoprazole; D008297:Male; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D009853:Omeprazole / Q000627:therapeutic use; D010295:Parietal Cells, Gastric / Q000378:metabolism*; D010890:Pirenzepine / Q000627:therapeutic use; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D011899:Ranitidine / Q000627:therapeutic use; D011970:Receptors, Histamine H2 / Q000378:metabolism*; D011976:Receptors, Muscarinic / Q000378:metabolism*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D018727:Muscarinic Antagonists; D054328:Proton Pump Inhibitors; D011970:Receptors, Histamine H2; D011976:Receptors, Muscarinic; D064747:Lansoprazole; D064750:Rabeprazole; D010890:Pirenzepine; D011899:Ranitidine; D009853:Omeprazole